IBD

Takeda Supports the Canadian IBD Research Consortium's $1 Million Pioneer Grant for Second Year

Retrieved on: 
Tuesday, February 13, 2024
Ulcerative colitis, Crohn's disease, Randomized controlled trial, Letter, Physician, Quality of life, McGill University, EST, Inflammatory bowel disease, Associate, Patient, CIRC, RCT, IBD, Disease, Research, Partnership

TORONTO, Feb. 13, 2024 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to announce its support of the Canadian Inflammatory Bowel Disease Research Consortium's (CIRC) $1 million PIONEER Grant in its second year.

Key Points: 
  • TORONTO, Feb. 13, 2024 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to announce its support of the Canadian Inflammatory Bowel Disease Research Consortium's (CIRC) $1 million PIONEER Grant in its second year.
  • This grant, with Takeda contributing $500,000 of the $1,000,000 award, will continue to support high-quality, impactful Canadian clinical research to improve patient outcomes and quality of life for people living with inflammatory bowel disease (IBD).
  • "We are immensely proud of our research community, this program and are grateful for Takeda partnership and dedication to advancing research in Canada."
  • "The PIONEER Grant, established through $1,000,000 in support from Takeda, gives Canadian IBD researchers an amazing and truly unique opportunity to conduct practice changing investigator-initiated research.

Palisade Bio Provides Corporate Update and Reiterates Guidance

Retrieved on: 
Tuesday, February 13, 2024
Therapy, Ulcerative colitis, Receipt, Completeness, MHP, Exercise, Internet, Doctor of Pharmacy, PDE4B, UC, Inflammatory bowel disease, Patient, IBD, Initiate, Trial of the century, Pharmaceutical industry

Carlsbad, CA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today provided a corporate update and reiterated upcoming milestones.

Key Points: 
  • “We continue to make significant development progress with PALI-2108, our lead program.
  • The program is providing us with a growing body of data that we find encouraging, including support for a precision medicine approach,” commented J.D.
  • Although smaller, we believe the reconstituted board better matches our stage of development while retaining ethnic and gender diversity.
  • PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4B (PDE4B) inhibitor prodrug in development for patients affected by UC.

EQS-News: Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)

Retrieved on: 
Tuesday, February 13, 2024
Therapy, Ulcerative colitis, European, A12, UC, Abstract, Patient, IBD, Symposium, Congress, Symposium (Plato), Ulcer, Euronext Paris, ECCO, Pharmaceutical industry

“We are delighted that all four submitted abstracts have been accepted for presentations at ECCO.

Key Points: 
  • “We are delighted that all four submitted abstracts have been accepted for presentations at ECCO.
  • We look forward to scientific exchange with the IBD community at ECCO,” said Sheldon Sloan, M.D., M. Bioethics, Chief Medical Officer of Abivax.
  • (Germany), on February 23, 2024, at 7:15-8:15 a.m. CET in room A12.
  • The Symposium will be broadcasted live and is accessible publicly here .

Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023

Retrieved on: 
Tuesday, February 13, 2024
New Drug Application, GSK, Cancer Research UK, JPY, DSM-IV codes, IPK, Trial of the century, EP4, GPR35, GPR52, Genentech, Neurocrine Biosciences, Deficit spending, Therapy, IBD, G&A, Glutamate (neurotransmitter), Partnership, Pfizer, Cerebral vasospasm, Senior, GPCR, NAM, Acquisition, FDA, Inflammatory Bowel Diseases, Schizophrenia, Patient, Tokyo Stock Exchange, Medicine, IPJ, Insomnia, Movement, Pharmaceutical industry

Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.

Key Points: 
  • Tokyo, Japan and Cambridge, UK, 13 February 2024 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the 12 months ended 31 December 2023.
  • Chris Cargill, President & CEO of Sosei Heptares, commented: “2023 has been a transformational year for Sosei Group and the progress made by our teams across all areas of the business has been exceptional.
  • Marketing approval for PIVLAZ® in South Korea – for the prevention of cerebral vasospasm and related conditions after aneurysmal subarachnoid hemorrhage (“aSAH”) securing.
  • A Phase 1 study of NBI-1117569 has begun and a Phase 1 study of NBI-1117567 is expected to begin in 2024.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
Monday, February 12, 2024
Pomerantz, Court, ALS, Person, Prior, Food, Complaint, District court, Apoptosis, Ext, AMX0035, Patient, LLP, IBD, Evercore, Action Replay, Amyotrophy, Prescription, Pharmaceutical industry

NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

AMYLYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Amylyx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, February 10, 2024
AMX0035, Prescription, P.C, Food, District court, Apoptosis, ALS, BBC World Service, Investor's Business Daily, Patient, Complaint, Amyotrophy, Person, Telephone, Evercore, IBD, Court, Pharmaceutical industry

Investors have until April 9, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 9, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Click here to participate in the action.
  • Amylyx is a commercial-stage biotechnology company that engages in the discovery and development of treatments for Amyotrophic Lateral Sclerosis ("ALS"), also known as Lou Gehrig's disease, and other neurodegenerative diseases.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

Retrieved on: 
Thursday, February 8, 2024
IBD, Trial of the century, Division, Inflammatory bowel disease, Therapy, CAB, Nutrition, DRS, Mount Sinai Health System, Ulcerative colitis, Associate, Pharmaceutical industry

Drs.

Key Points: 
  • Drs.
  • Sands and Rieder will be advising Palisade on the advancement of its product candidates from preclinical studies to clinical trials.
  • “We are committed to advancing the treatment landscape for Inflammatory Bowel Disease (IBD) and believe that the appointment of these preeminent key opinion leaders will assist in the development of a precision approach for IBD treatment,” commented J.D.
  • Finley, Chief Executive Officer of Palisade.

Biora Therapeutics Announces Participation in Canaccord Genuity Inflammatory Bowel Disease Symposium

Retrieved on: 
Thursday, February 8, 2024
Steps, Inflammatory bowel disease, IBD, SAN, Interest, Therapy, Canaccord Genuity

SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc .

Key Points: 
  • SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc .
  • (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will participate in the Inflammatory Bowel Disease Symposium hosted virtually by Canaccord Genuity Capital Markets on Wednesday, February 28, 2024.
  • Ariella Kelman, M.D., Chief Medical Officer, will participate in the panel titled “The Next Evolutionary Steps in Addressing IBD,” beginning at 10:00 AM Eastern / 7:00 AM Pacific time.
  • Interested parties may contact their Canaccord Genuity representative to request registration details for the virtual event.

Spyre Therapeutics Announces Three Abstracts Accepted for Presentation at the 19th Annual Congress of the European Crohn's and Colitis Organisation

Retrieved on: 
Thursday, February 8, 2024
Paragon, Abstract, IBD, Congress, Inflammatory bowel disease, Clinical trial, Engineering, TL1A, SVP, SYRE, ECCO, Therapy, Medicine, Doctor of Philosophy, Treatment, Pharmaceutical industry

SPY001 is a fully optimized and half-life extended antibody targeting α4β7 and SPY002 is a fully optimized and half-life extended antibody targeting TL1A, both in development for the treatment of IBD.

Key Points: 
  • SPY001 is a fully optimized and half-life extended antibody targeting α4β7 and SPY002 is a fully optimized and half-life extended antibody targeting TL1A, both in development for the treatment of IBD.
  • "We are thrilled to share preclinical findings supporting our two lead programs, SPY001 and SPY002, during the ECCO Congress," said Joshua Friedman, MD, PhD, SVP of Clinical Development of Spyre.
  • "The preclinical potency, selectivity, and drug-like properties of these investigational antibodies match our ideal product profiles.
  • We are eager to initiate Phase 1 clinical studies in each program this year."

San Jose Wellness Center, NexGen Health, Elevates Wellness Offerings with the Introduction of BPC 157 Peptide Therapy

Retrieved on: 
Wednesday, February 7, 2024
NexGen, IBD, Inflammation, SAN, Tears, Regenerative medicine, Wound, Regeneration, Wound healing, Inflammatory bowel disease, Patient, Irritable bowel syndrome, BPC, Abrasion, Arthritis, IBS, Health, Pain management, Quality of life, Tropical ulcer, Arthralgia

SAN JOSE, Calif., Feb. 7, 2024 /PRNewswire/ -- NexGen Health, a prominent wellness clinic located in San Jose, California, is pleased to announce the integration of BPC 157 Peptide Therapy into its comprehensive suite of specialized wellness services. This cutting-edge therapy is poised to invigorate the body's innate healing processes, offering renewed hope to individuals seeking optimal health and well-being.

Key Points: 
  • NexGen Health improves patient care by introducing BPC 157 peptide therapy in San Jose, California, empowering healing, and wellness.
  • SAN JOSE, Calif., Feb. 7, 2024 /PRNewswire/ -- NexGen Health, a prominent wellness clinic located in San Jose, California, is pleased to announce the integration of BPC 157 Peptide Therapy into its comprehensive suite of specialized wellness services.
  • "Our commitment to offering BPC 157 Peptide Therapy reflects our passion for providing our patients with the latest advancements in regenerative medicine," says Ilbra Petros, Director of NexGen Health.
  • Our commitment to offering BPC 157 Peptide Therapy reflects our passion for providing our patients with the latest advancements in regenerative medicine," says Ilbra Petros, Director of NexGen Health.